• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Analyst Landscape: 5 Takes On Avantor

    6/28/24 12:01:26 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    Across the recent three months, 5 analysts have shared their insights on Avantor (NYSE:AVTR), expressing a variety of opinions spanning from bullish to bearish.

    Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 4 1 0 0
    Last 30D 0 1 0 0 0
    1M Ago 0 0 0 0 0
    2M Ago 0 1 0 0 0
    3M Ago 0 2 1 0 0

    Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.8, a high estimate of $30.00, and a low estimate of $25.00. Observing a 2.29% increase, the current average has risen from the previous average price target of $26.20.

    price target chart

    Diving into Analyst Ratings: An In-Depth Exploration

    In examining recent analyst actions, we gain insights into how financial experts perceive Avantor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Luke Sergott Barclays Lowers Overweight $25.00 $28.00
    Catherine Schulte Baird Lowers Outperform $26.00 $27.00
    Justin Bowers Deutsche Bank Raises Hold $25.00 $23.00
    Luke Sergott Barclays Raises Overweight $30.00 $27.00
    Vijay Kumar Evercore ISI Group Raises Outperform $28.00 $26.00

    Key Insights:

    • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avantor. This information provides a snapshot of how analysts perceive the current state of the company.
    • Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avantor compared to the broader market.
    • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Avantor's stock. This comparison reveals trends in analysts' expectations over time.

    To gain a panoramic view of Avantor's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

    Stay up to date on Avantor analyst ratings.

    Delving into Avantor's Background

    Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.

    Unraveling the Financial Story of Avantor

    Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

    Revenue Challenges: Avantor's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -5.65%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

    Net Margin: Avantor's net margin excels beyond industry benchmarks, reaching 3.6%. This signifies efficient cost management and strong financial health.

    Return on Equity (ROE): Avantor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.14%, the company may face hurdles in achieving optimal financial performance.

    Return on Assets (ROA): Avantor's ROA stands out, surpassing industry averages. With an impressive ROA of 0.47%, the company demonstrates effective utilization of assets and strong financial performance.

    Debt Management: Avantor's debt-to-equity ratio stands notably higher than the industry average, reaching 1.0. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

    The Significance of Analyst Ratings Explained

    Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

    Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    1/5/2026$12.00Outperform → In-line
    Evercore ISI
    12/17/2025$9.00Hold → Underperform
    Jefferies
    12/15/2025$13.00Buy → Neutral
    BofA Securities
    11/4/2025Outperform → Mkt Perform
    Raymond James
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    More analyst ratings

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dingemans Simon was granted 6,225 shares (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    1/12/26 5:06:55 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Dingemans Simon

    3 - Avantor, Inc. (0001722482) (Issuer)

    1/12/26 5:05:31 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    12/18/25 8:17:12 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    12/4/25 4:29:41 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    11/10/25 5:11:45 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Avantor from Outperform to In-line and set a new price target of $12.00

    1/5/26 8:46:17 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Jefferies with a new price target

    Jefferies downgraded Avantor from Hold to Underperform and set a new price target of $9.00

    12/17/25 8:49:45 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by BofA Securities with a new price target

    BofA Securities downgraded Avantor from Buy to Neutral and set a new price target of $13.00

    12/15/25 9:53:32 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026

    RADNOR, Pa., Jan. 12, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February, 11, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avanto

    1/12/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference

    RADNOR, Pa., Jan. 5, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Emmanuel Ligner, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at approximately 8:15 a.m. Pacific Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be a

    1/5/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Ligner Emmanuel bought $993,125 worth of shares (87,500 units at $11.35), increasing direct ownership by 45% to 283,424 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    11/17/25 5:45:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026

    RADNOR, Pa., Jan. 12, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February, 11, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avanto

    1/12/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials